-
December 7–10, 2019
Orange County Convention Center, Orlando, FL
Dana-Farber at ASH 2019
As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute participated in many ways at the 61st Annual Meeting of the American Society of Hematology (ASH).
Attendees learned the latest about our adult and pediatric clinical programs,
discoveries, innovations, and clinical trials.
Follow along on Twitter: #ASH19
Dana-Farber Researchers Presented More Than 40 Studies at ASH 2019
Oral presentations included:
Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission
Presenter/Author: H. Moses Murdock, BS, R. Coleman Lindsley, MD, PhD
Saturday, December 7, 8:45 a.m.
View
Abstract
Read Findings
HemOnc Today coverage
AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo
Presenter/Author: Yu-Tzu Tai, PhD
Saturday, December 7, 10:00 a.m.
View Abstract
Read Findings
A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies
Presenter/Author: Jacqueline
Garcia, MD
Saturday, December 7, 3:15 p.m.
View Abstract
Read Findings
ASH Clinical News
coverage
Oncology Times coverage
-
Dr. Garcia presented results of a trial using venetoclax in stem cell transplants regimens for patients with high-risk myeloid cancers.
-
Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Presenter/Author: Mark Bustoros, MD
Monday, December 9, 7:45 a.m.
View Abstract
Read Findings
ASCO Post coverage
HemOnc Today coverage
-
Dr. Bustoros presented data from a phase 2 clinical trial of three oral drugs showing high response rate with tolerable effects in high risk smoldering multiple myeloma.
-
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
Presenter/Author: Reid W. Merryman, MD
Monday, December 9, 2:45 p.m.
View Abstract
Read Findings
The Cancer Letter coverage
HemOnc Today coverage
-
Dr. Merryman presented a new analysis showing that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma, easing concerns that these patients are at heightened risk for severe immune-related complications.
-
Full Roster of Presentations by Dana-Farber Faculty
Our presentations were part of the ASH Education Program, Scientific Program, and/or Special Scientific Symposia.
December 7 Presentations
December 8 Presentations
December 9 Presentations
-
Video Highlights
Watch Dana-Farber faculty summarize research they presented at ASH 2019